본문으로 건너뛰기
← 뒤로

Lymphocyte-to-Monocyte Ratio as a Practical Biomarker for Immunotherapy Response in Hepatocellular Carcinoma.

1/5 보강
Hepatology research : the official journal of the Japan Society of Hepatology 📖 저널 OA 8.5% 2024: 0/1 OA 2025: 0/23 OA 2026: 8/70 OA 2024~2026 2026 Vol.56(4) p. 399-400 Inflammatory Biomarkers in Disease P
TL;DR Among these agents, the combination of durvalumab and tremelimumab (Dur/Tre), known as the STRIDE regimen, has reshaped the treat-ment landscape of unresectable hepatocellular carcinoma.
Retraction 확인
출처
PubMed DOI OpenAlex Semantic 마지막 보강 2026-05-01
OpenAlex 토픽 · Inflammatory Biomarkers in Disease Prognosis Hepatocellular Carcinoma Treatment and Prognosis Cancer Immunotherapy and Biomarkers

Tanaka S

📝 환자 설명용 한 줄

Among these agents, the combination of durvalumab and tremelimumab (Dur/Tre), known as the STRIDE regimen, has reshaped the treat-ment landscape of unresectable hepatocellular carcinoma.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Satoshi Tanaka (2026). Lymphocyte-to-Monocyte Ratio as a Practical Biomarker for Immunotherapy Response in Hepatocellular Carcinoma.. Hepatology research : the official journal of the Japan Society of Hepatology, 56(4), 399-400. https://doi.org/10.1111/hepr.70093
MLA Satoshi Tanaka. "Lymphocyte-to-Monocyte Ratio as a Practical Biomarker for Immunotherapy Response in Hepatocellular Carcinoma.." Hepatology research : the official journal of the Japan Society of Hepatology, vol. 56, no. 4, 2026, pp. 399-400.
PMID 41355725 ↗
DOI 10.1111/hepr.70093

같은 제1저자의 인용 많은 논문 (5)